Univercells appoints Douglas A. Neugold as chairman of its board of directors


A seasoned executive with expertise in single-use bioprocess solutions, Neugold will help Univercells prepare and develop its US activities

Univercells appoints Douglas A. Neugold as chairman of its board of directors

Univercells SA, a technology company dedicated to delivering innovative and cost-effective biomanufacturing solutions, announces the appointment of Douglas Neugold as chairman of its board of directors.

Mr Neugold has extensive industry experience in various areas, with more than 30 years as a successful executive and manager in global technology companies, most recently as chairman and CEO of NASDAQ traded ATMI. Prior to that he was an executive at Johnson Matthey, helping to build their global electronic and specialty materials business.

While at ATMI Inc, Mr Neugold built and led the organisation to a global leadership position as the key supplier of sophisticated materials and delivery systems used in the manufacture of leading edge computer chips and displays, with over 700 employees and facilities throughout the US, Asia and Europe. As the electronics industry matured, Mr Neugold led the company into other high growth technology intensive industries, most notably single-use systems for bioprocessing.

Neugold’s appointment brings a wealth of relevant experience to Univercells, which he will leverage to provide insight and guidance on its long-term strategic development plan, notably the development of Univercells’ US-based activities. Univercells will benefit from Mr Neugold’s deep understanding of the biopharmaceutical sector and players to build long-lasting relationships with the US federal agencies and initiate strategic industrial and institutional partnerships.

“I have been following the growth and evolution of Univercells from the beginning, serving as a strategic advisor. I am proud and excited to take a more active role in helping drive its further development and achieve its objectives, which I see as making significant contributions to improving global health, most especially in emerging markets” said Mr Neugold.

Sign up for your free email newsletter